Epidemiological significance of detection of SARS-CoV-2 RNA among different groups of population of Moscow and Moscow Region during the COVID-19 outbreak

Cover Page


Cite item

Abstract

The Central Research Institute of Epidemiology of Rospotrebnadzor presents priority data obtained from the largescale population PCR-based study of the changes in the rates of circulation of SARS-CoV-2 among relatively healthy residents of Moscow and Moscow Region.

Full Text

From 6/4/2020 to 24/5/2020, scientists from the Central Research Institute of Epidemiology conduc­ted a population-based study, which made it possible to estimate the rate of SARS-CoV-2 circulation among residents of Moscow and Moscow Region. The study included a total of 75,940 relatively healthy individuals displaying no symptoms of respiratory diseases. In ad­dition, with an increase in the number of COVID-19 cases in Moscow Region, different categories of pa­tients were examined (n = 83,699). The studies were performed by using the AmpliSens® Cov-Bat-FL test system (Registration Certificate RZN 2014/1987 of 25/3/2020) designed and manufactured by the Central Research Institute of Epidemiology.

In the examined cohort of relatively healthy res­idents of Moscow Region, SARS-CoV-2 RNA was detected in 5,321 (7.01%) individuals (95% CI1 6.83­7.19%); the detection frequency for SARS-CoV-2 RNA was 7.12% (6.87-7.37%) in Moscow and 6.87% (6.60­7.14%) in Moscow Region, thus demonstrating no dif­ference in the SARS-CoV-2 RNA detection frequency in these constituent territories of Russia.

 

The dynamics of the analyzed indicator is highly important both for assessment of the epidemiological situation and for identification of its evolution pattern (Figure).

The rate of SARS-CoV-2 circulation among relatively healthy residents of Moscow and Moscow Region during the COVID-19 epidemic outbreak.

 

It should be noted that the rates of SARS-CoV-2 RNA detection varied quite considerably; the fluctu­ations were more noticeable in Moscow Region than in Moscow. For example, in Moscow Region, 5 peak values call for special attention: 11/4/2020 (15.2%), 28/4/2020-29/4/2020 (15.4 and 17.9%, respectively), 3/5/2020 (13.5%) and 7/5/2020 (14.7%).

The minimum values were observed during the overall decrease in the detection frequency of SARS- CoV-2 RNA and amounted to 2.7% (20/5/2020), 2.5% (21/5/2020) and 2.8% (24/5/2020). In Moscow, the peak values were slightly lower and amounted to 11.9% (16/4/2020), 11.0% (17/4/2020), 11.9% (21/4/2020), 11.2% (28/4/2020) and 10.4% (8/5/2020). The mini­mum values were also registered during the last days of the monitoring period from 23/5/2020 to 24/5/2020 (1.8% and 1.9%, respectively).

Based on the curve values of the frequency of SARS-CoV-2 RNA detection among the population, we singled out three time segments (6/4/2020-28/4/2020, 29/4/2020-12/5/2020 and 13/5/2020-24/5/2020), for which dynamic trends of the analyzed indicator were estimated. During 6/4/2020-28/4/2020, the moderate increase at positive growth rates of 1.3% and 3.0% per day was registered in Moscow and Moscow Region, respectively. In our opinion, the increasing number of potential sources of infection is indicative of intensifi­cation of the COVID-19 epidemic process in the stu­died territories of Russia.

In the middle of the monitoring period (29/4/2020­12/5/2020), Moscow and Moscow Region showed dif­ferences in the dynamics of the analyzed indicator. In Moscow, the frequency of SARS-CoV-2 RNA detec­tion in the population began decreasing at a moderate negative rate of 1.8% per day, while Moscow Region continued demonstrating moderate increase at a posi­tive rate of 3.3% per day.

The last 10 days of the monitoring period were characterized by rapidly decreasing frequency of SARS-CoV-2 RNA detection, demonstrating negative growth rates of 5.9% and 11.1% per day in Moscow and Moscow Region, respectively.

In the meantime, the positive trend in develop­ment of the COVID-19 epidemic process, which was suggested by the dynamics of the frequency of SARS- CoV-2 detection in the population, does not imply over­all epidemiological welfare. In our opinion, the rate of circulation of SARS-CoV-2 in a population is one of the indicators that can provide a quantitative assess­ment of the epidemiological situation. We compared mean frequencies of detection of SARS-CoV-2 RNA in the examined individuals at 7-9-days intervals from 6/4/2020 to 24/5/2020 (Table).

 

The mean frequency of detection of SARS-CoV-2 RNA in Moscow and Moscow Region, 6/4/2020-24/5/2020

Duration of study

Moscow

Moscow Region

%

95% confidence interval

%

95% confidence interval

6/4/2020-12/4/2020

7,04

6,13-8,04

11,66

10,09-13,39

28/4/2020-4/5/2020

7,60

6,90-8,35

8,53

7,63-9,50

16/5/2020-24/5/2020

3,30

2,93-3,70

3,39

3,06-3,75

It can be said that during the entire monitoring period, Moscow and Moscow Region demonstrated a substantial (3-4-fold; p < 0.001) decrease in the pro­portion of the individuals who were potential sources of infection, which, in our opinion, can serve as a pre­diction of further improvement of the epidemiological situation.

The obtained data indicate the effectiveness of the implemented epidemic control measures. The manda­tory self-isolation imposed in Moscow on 25/3/2020 began to have a significant effect resulting in a decrease in the proportion of individuals infected with SARS- CoV-2 approximately by the 6th -7th week (Figure). We assume that the time when the self-isolation in Mos­cow started having its impact and the time when the frequency of SARS-CoV-2 started decreasing can be indicative of the COVID-19 incubation period lasting more than 14 days as well as of the long duration of virus shedding in convalescent patients, though our as­sumption requires a thorough study [1].

At the same time, this improvement of the epide­miological situation is not sufficient for immediate and total lifting of the restrictive measures, as herd immu­nity against SARS-CoV-2 RNA has not been achieved yet. The preliminary data indicate that at the epidemic

stage defined as stabilization (by the dynamics of the COVID-19 incidence), from 16/5/2020 to 24/5/2020, the frequency of detection of specific antibodies to SARS-CoV-2 in the random selection of individuals in Moscow Region was 12-15%, thus totally correlating with our data on the virus circulation rate among po­pulation.

The detection of SARS-CoV-2 RNA in different groups of patients had high diagnostic significance. SARS-CoV-2 RNA was detected in 81.65% (81.18­82.11%) cases among the patients provisionally diag­nosed with acute respiratory viral infection. It means that amid the COVID-19 epidemic this etiological agent is the primary one for this specific disease. Among the patients diagnosed with pneumonia, which was sup­ported by the clinical evidence, SARS-CoV-2 RNA was detected in 70.92% (70.22-72.61%) cases. The fre­quency of detection of SARS-CoV-2 RNA in individu­als who were in contact with COVID-19 patients was quite high, amounting to 65.78% (65.23-66.33%). The fact that 2/3 of the exposed individuals were infected indicates a high level of SARS-CoV-2 contagiousness and corresponds to the later model of the COVID-19 spread [2, 3]. The separate group included patients ex­amined by the doctor’s order. During the epidemic, the frequency of SARS-CoV-2 RNA detection was 77.34% (76.53-78.13%).

The obtained results demonstrate that PCR-based detection of SARS-CoV-2 during the COVID-19 epi­demic outbreak in Russia has critical and independent significance. Firstly, the examination for presence of SARS-CoV-2 RNA is important for timely identifica­tion and isolation of potentially infectious individuals as well as for etiological differential diagnosis to distin­guish from other acute respiratory diseases and influen­za, which has fundamental significance in prevention of SARS-CoV-2 spread. Secondly, the accurate identifica­tion of the etiology of a disease is an essential prerequi­site for the correct decision regarding case management. Thirdly, the performed dynamic population-based study showed that obtained results are important in assessing the stage of the COVID-19 epidemic development [4].

In our study, during the first week (6/4/2020­12/4/2020) the frequency of detection of SARS-CoV-2 RNA among randomly selected healthy people was 7.04% and 11.66% in Moscow and Moscow Region, respectively. It means that 1 of 10-13 individuals who consider themselves healthy is infected and is a po­tential source of infection for other people. Such virus carriers are responsible for the high intensity of the epi­demic process in Moscow and Moscow Region.

In the middle of the studied period (28/4/2020­4/5/2020) the frequency of detection of sArS-CoV-2 RNA remained unchanged (7.60%) in Moscow, while the detection frequency in Moscow Region demon­strated a slight decrease (8.53%). The highly important fact is that the proportion of the infected individuals reduced significantly during the last week (16/5/2020­24/5/2020). In Moscow and Moscow Region, SARS- CoV-2 RNA was detected in 3.30 and 3.39% of the ex­amined individuals, respectively.

Thus, the frequency of SARS-CoV-2 circulation in a population is an essential integrative epidemiolo­gical indicator providing reliable assessment of the in­tensity of the epidemic process and effectiveness of the epidemic control measures [5].

The mass, population-based screening for pres­ence of SARS-CoV-2 RNA is a vitally important epi­demic control method providing real-time and unbi­ased information about development of the epidemic process. Considering their significance for assessment of the epidemiological situation, proportions of infec­ted individuals among healthy groups, which demon­strate rates of virus circulation among the population, most likely, will be used as one of the monitoring parameters in the system of epidemiological surveil­lance [5, 6].

×

About the authors

Vasily G. Akimkin

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0003-4228-9044
D. Sci. (Med.), Full Member of the Russian Academy of Sciences, Director Россия

Stanislav N. Kuzin

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Author for correspondence.
Email: drkuzin@list.ru
ORCID iD: 0000-0002-0616-9777
D. Sci. (Med.), prof., Head, Laboratory of viral hepatitis Россия

Olga Yu. Shipulina

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0003-4679-6772
PhD (Med.), Head of subdivisions, of laboratory medicine and laboratory services promotion, Department of molecular diagnostics and epidemiology Россия

Svetlana B. Yatsyshina

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0003-4737-941X
PhD (Biol.), senior researcher, Head, Department of molecular diagnostics and epidemiology Россия

Elena V. Tivanova

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0003-1286-2612
Head, area of laboratory medicine and laboratory services promotion, Department of molecular diagnostics and epidemiology Россия

Anna V. Kalenskaya

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0002-9126-1155
Deputy head, area of laboratory medicine and laboratory services promotion for customer service, Department of molecular diagnostics and epidemiology Россия

Irina V. Solovieva

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0002-3136-9500
Deputy head, area of laboratory medicine and laboratory services promotion for customer service, Department of molecular diagnostics and epidemiology Россия

Marina A. Vershinina

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0001-8582-5199
leading consultant in laboratory medicine, Department of molecular diagnostics and epidemiology Россия

Olga A. Kvasova

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0002-4545-1804
epidemiologist, Laboratory of Infections associated with the provision of medical assistance Россия

Antonina A. Ploskireva

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0002-3612-1889
D. Sci. (Med.), Deputy Director Россия

Marina V. Mamoshina

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0002-1419-7807
junior researcher, Department of molecular diagnostics and epidemiology Россия

Mariya A. Elkina

Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: fake@neicon.ru
ORCID iD: 0000-0003-4769-6781
junior researcher, Department of molecular diagnostics and epidemiology Россия

Elena E. Andreeva

Office of the Federal Service for Supervision of Consumer Rights Protection and Human Well-Being in Moscow

Email: fake@neicon.ru
ORCID iD: 0000-0001-6687-7276
D. Sci. (Med.), prof., Head Россия

Aleksandr V. Ivanenko

Center for Hygiene and Epidemiology in the City of Moscow

Email: fake@neicon.ru
ORCID iD: 0000-0002-7122-017X
chief physician Россия

Olga M. Mikailova

Office of the Federal Service for Supervision of Consumer Rights Protection and Human Well-Being in Moscow Region

Email: fake@neicon.ru
ORCID iD: 0000-0003-3842-6368
PhD (Med.), Head Россия

References

  1. Zheng S., Fan J., Yu F., Feng B., Lou B., Zou Q., et al. Viral load dynamics and disease severity in patients infected with SARSCoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ. 2020; 369: m1443. DOI: http://doi.org/10.1136/bmj.m1443
  2. Sanche S., Lin Y.T., Xu C., Romero-Severson E., Hengartner N., Ke R. Contagiousness and rapid spread of severe acute respiratory syndrome Coronavirus 2. Emerg. Infect. Dis. 2020; 26(7): 10.3201/eid2607.200282. DOI: http://doi.org/10.3201/eid2607.200282
  3. Courtemanche C., Garuccio J., Le A., Pinkston J., Yelowitz A. Strong social distancing measures in the United States reduced the COVID-19 growth rate. Health Aff. (Millwood). 2020; 101377hlthaff202000608. DOI: http://doi.org/10.1377/hlthaff.2020.00608
  4. Omori R., Mizumoto K., Chowell G. Changes in testing rates could mask the novel coronavirus disease (COVID-19) growth rate. Int. J. Infect. Dis. 2020; 94: 116‐8. DOI: http://doi.org/10.1016/j.ijid.2020.04.021
  5. Signorelli C., Scognamiglio T., Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed. 2020; 91(3-S): 175‐9. DOI: http://doi.org/10.23750/abm.v91i3-S.9511
  6. Shearer F.M., Moss R., McVernon J., Ross J.V., McCaw J.M. Infectious disease pandemic planning and response: Incorporating decision analysis. PLoS Med. 2020; 17(1): e1003018. DOI: http://doi.org/10.1371/journal.pmed.1003018

Supplementary files

Supplementary Files
Action
1. JATS XML
2. The rate of SARS-CoV-2 circulation among relatively healthy residents of Moscow and Moscow Region during the COVID-19 epidemic outbreak.

Download (54KB)

Copyright (c) 2020 Akimkin V.G., Kuzin S.N., Shipulina O.Y., Yatsyshina S.B., Tivanova E.V., Kalenskaya A.V., Solovieva I.V., Vershinina M.A., Kvasova O.A., Ploskireva A.A., Mamoshina M.V., Elkina M.A., Andreeva E.E., Ivanenko A.V., Mikailova O.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies